Document Detail


Use of inhaled nitric oxide in the new born period: results from the European Inhaled Nitric Oxide Registry.
MedLine Citation:
PMID:  20219040     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIMS: The aim of this study was to present data relating to the use of inhaled nitric oxide (iNO) in newborn infants included in the European Inhaled Nitric Oxide Registry. METHODS: Demographic, clinical and therapeutic data from seven European centres are reported. Univariate analyses were performed to identify factors associated with acute response to iNO and survival without extra corporeal membrane oxygenation (ECMO). RESULTS: A total of 112 newborn infants received iNO, with 40% being less than 34 weeks gestational age. The commonest indication for iNO was secondary pulmonary hypertension. Acute response to iNO was more common in infants with a higher oxygenation index (median OI 32.7 vs 22.6, p = 0.040), although acute response did not predict survival without ECMO. Infants who survived without ECMO had a lower OI prior to therapy (median OI 24 vs 43, p = 0.009), were commenced on a higher starting dose (median dose 20 ppm vs 10 ppm p = 0.013) and received a lower maintenance dose (median dose 10 vs 17 ppm, p = 0.027) than those who died or received ECMO. CONCLUSION: Collating and reporting data about iNO therapy in neonates across a number of European centres using a web-based system is feasible. These data may be used to monitor the clinical use of iNO, identify adverse effects, generate research hypotheses and promote high standards in the clinical use of iNO.
Authors:
Chris Dewhurst; Hafis Ibrahim; Sylvia Göthberg; Baldvin Jónsson; Nimish Subhedar;
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-03-05
Journal Detail:
Title:  Acta paediatrica (Oslo, Norway : 1992)     Volume:  99     ISSN:  1651-2227     ISO Abbreviation:  Acta Paediatr.     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-06-17     Completed Date:  2010-08-17     Revised Date:  2010-10-15    
Medline Journal Info:
Nlm Unique ID:  9205968     Medline TA:  Acta Paediatr     Country:  Norway    
Other Details:
Languages:  eng     Pagination:  854-60     Citation Subset:  IM    
Affiliation:
Liverpool Women's Hospital, Liverpool, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Inhalation
Analysis of Variance
Europe
Extracorporeal Membrane Oxygenation
Female
Humans
Infant, Newborn
Infant, Premature
Infant, Premature, Diseases / therapy*
Male
Nitric Oxide / administration & dosage*
Persistent Fetal Circulation Syndrome / therapy*
Pilot Projects
Registries
Treatment Outcome
Chemical
Reg. No./Substance:
10102-43-9/Nitric Oxide
Investigator
Investigator/Affiliation:
Sylvia Göthberg / ; Baldvin Jonsson / ; Nimish Subhedar / ; Paula Rautiainen / ; Gitte Esberg / ; Jens Groegaard / ; Atle Dagbjartsson /
Comments/Corrections
Comment In:
Acta Paediatr. 2010 Sep;99(9):1283   [PMID:  20456263 ]
Erratum In:
Acta Paediatr. 2010 Jul;99(7):1212

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The enigma of the welfare state: excellent child health prerequisites--poor subjective health.
Next Document:  Faecal calprotectin concentrations in children with functional gastrointestinal disorders diagnosed ...